These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6305851)

  • 1. Characterization of T lymphocytes mediating in vivo protection against RSV-induced murine sarcomas.
    Prat M; Di Renzo MF; Comoglio PM
    Int J Cancer; 1983 Jun; 31(6):757-64. PubMed ID: 6305851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.
    Prat M; Bretti S; Amedeo M; Landolfo S; Comoglio PM
    J Immunol; 1987 Jun; 138(12):4530-3. PubMed ID: 3035023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.
    Comoglio PM; Prat M; Bretti S
    Immunology; 1985 Feb; 54(2):289-95. PubMed ID: 2578431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. src-specific immune regression of Rous sarcoma virus-induced tumors.
    Gelman IH; Hanafusa H
    Cancer Res; 1993 Feb; 53(4):915-20. PubMed ID: 8381333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lyt phenotype of H-2b CTL effectors and precursors specific for the SV40 transplantation rejection antigen.
    Flyer DC; Anderson RW; Tevethia SS
    J Immunol; 1982 Dec; 129(6):2368-71. PubMed ID: 6292288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between tumor-specific surface antigens and src gene expression in Rous sarcoma virus-induced rat tumors.
    Kuzumaki N; Minakawa H; Matsuo T; Haraguchi S; Yoshida TO
    Eur J Cancer Clin Oncol; 1983 Mar; 19(3):401-9. PubMed ID: 6305667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector mechanism of tumor immunity in murine plasmacytoma.
    Chen YH; Anderson AB
    Cancer Res; 1988 Mar; 48(6):1398-403. PubMed ID: 3257896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action.
    Evans R
    Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of immune interferon is regulated by more than T cell subset: Lyt-1,2,3 and Qat-5 phenotypes of murine T lymphocytes involved in IFN-gamma production in primary and secondary mixed lymphocyte reaction.
    Landolfo S; Kirchner H; Simon MM
    Eur J Immunol; 1982 Apr; 12(4):295-9. PubMed ID: 6178601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY; Singleton A; Cillari E; Howard JG
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
    Suzuki R; Suzuki S; Ebina N; Kumagai K
    J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No expression of a Rous sarcoma virus-induced tumor antigen in mammalian cells infected with retroviruses transducing other oncogenes of the src gene family.
    Kuzumaki N; Yamagiwa S; Oikawa T
    J Natl Cancer Inst; 1985 Apr; 74(4):889-92. PubMed ID: 2985859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
    Giovarelli M; Santoni A; Forni G
    J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells.
    Bianchi R; Fioretti MC; Romani L; Grohmann U; Cenci E; Puccetti P
    Int J Cancer; 1990 Oct; 46(4):653-7. PubMed ID: 2120136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY; Howard JG; Hale C
    J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of anti-tumor immunity in low-responder mice by various biological response modifiers: analysis of effector mechanism.
    Toko T; Fujimoto S
    Jpn J Cancer Res; 1989 Dec; 80(12):1212-9. PubMed ID: 2560774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.